Vimian Group AB (publ) (STO:VIMIAN)

Market Cap	22.71B
Revenue (ttm)	4.29B
Net Income (ttm)	211.97M
Shares Out	523.20M
EPS (ttm)	0.42
PE Ratio	103.15
Forward PE	36.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	282,634
Average Volume	664,637
Open	45.00
Previous Close	44.85
Day's Range	43.40 - 45.20
52-Week Range	25.18 - 47.30
Beta	1.58
RSI	55.08
Earnings Date	Feb 13, 2025

About Vimian Group AB

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the I...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 1,100
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: VIMIAN

Financial Performance

In 2024, Vimian Group AB's revenue was 374.80 million, an increase of 12.98% compared to the previous year's 331.73 million. Earnings were 18.50 million, an increase of 88.01%.

Financial numbers in EUR